hu14.18K322A

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
0120112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2015
Review
2015
BACKGROUND Addition of anti-GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side… (More)
  • table I
Is this relevant?
2014
2014
PURPOSE The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines… (More)
Is this relevant?
2012
2012
Targeted monoclonal antibodies (mAb) can be used therapeutically for tumors with identifiable antigens such as disialoganglioside… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
UNLABELLED The hu14.18K322A variant of the GD2-targeting antibody hu14.18 has been shown to elicit a level of antibody-dependent… (More)
Is this relevant?
2011
2011
9523 Background: Immunotherapy, including combination anti-GD2 mAb ch14.18 and cytokines, improves the outcome of patients with… (More)
Is this relevant?